Active Filter(s):
Details:
XWPharma expects to use proceeds to advance clinical development of the company’s lead investigational programs: XW10172, a GABAB receptor agonist intended for the treatment of sleep disorders in narcolepsy, Parkinson’s disease and other neurodegenerative diseases.
Lead Product(s): XW10172
Therapeutic Area: Sleep Product Name: XW10172
Highest Development Status: Phase I Product Type: Small molecule
Partner/Sponsor/Collaborator: Panacea Venture
Deal Size: $40.0 million Upfront Cash: Undisclosed
Deal Type: Series C Financing September 17, 2020